TCS Industries Limited (China-sourced API supplier) supplies Toceranib Phosphate — API CAS 874819-74-6 for pharmaceutical B2B procurement — COA, MSDS, and technical documentation available on request.
> Overview
| Product Name | Toceranib Phosphate |
|---|---|
| Structural Formula |  |
| CAS Number | 874819-74-6 |
| Molecular Formula | C22H28FN4O6P |
| Molecular Weight | 494.5 g/mol |
| InChIKey | AOORBROPMMRREB-HBPAQXCTSA-N |
| SMILES | Available on request where applicable |
| Appearance | Off-white to pale yellow crystalline powder |
| Purity / Grade | By agreed specification and batch COA |
| Storage | Room temperature |
Toceranib Phosphate (CAS 874819-74-6) is a multi-targeted receptor tyrosine kinase inhibitor with the formula C₂₂H₂₂FN₅O·H₃PO₄ (free base MW 395.44). It inhibits split kinase family RTKs including VEGFR2, PDGFRα, PDGFRβ, Kit, and Flt3. Toceranib is used for canine mast cell tumors and is the first targeted anticancer therapy approved for veterinary use.
TCS Industries Limited, a Hong Kong-based trading and sourcing company, supplies Toceranib Phosphate API for veterinary oral oncology formulation programs.
> Applications
Canine mast cell tumor treatment
Toceranib Phosphate is formulated as film-coated tablets (Palladia, Zoetis) at 10 mg, 15 mg and 50 mg strengths. Dosing is 3.25 mg/kg every other day. Objective response rates (complete + partial response) of approximately 37–42% have been reported in recurrent or non-resectable MCTs. London et al. (Clin Cancer Res, 2009, 15:3856–3865) described the pivotal clinical trial establishing efficacy in canine MCT.
Off-label veterinary oncology applications
Toceranib is used off-label by veterinary oncologists for various solid tumors in dogs including carcinomas, sarcomas, and metastatic disease. Some veterinary practices combine toceranib with metronomic chemotherapy protocols (low-dose cyclophosphamide). Off-label dose optimization and monitoring for adverse effects (GI toxicity, neutropenia, proteinuria) are managed on a case-by-case basis.
> Sourcing & Supply
TCS Industries Limited supports development, qualification and commercial purchasing discussions for Toceranib Phosphate with buyers in Australia, New Zealand, Canada and South Korea.
- Development and qualification quantities: 10 g to 1 kg packs for formulation trials, analytical method validation, and veterinary oncology drug registration submissions.
- Pallet quantities and production campaigns: repeat supply is coordinated against packaging, lead time, annual demand and destination-market import requirements.
> Quality & Documentation
Key specification parameters include assay (≥98.0%), related substances, water content, residual solvents, heavy metals, and microbial limits. Off-white to pale yellow crystalline powder (as phosphate salt). Slightly soluble in water. Identity by HPLC, NMR, and MS. Meets in-house veterinary pharmaceutical specifications. COA and MSDS are standard.
> Packaging
Toceranib phosphate is an off-white to pale yellow crystalline powder. Standard packaging includes sealed glass vials or foil bags under nitrogen (10 g, 50 g, 100 g, or 500 g). Store at controlled room temperature (15–25 °C). Protect from light and moisture. Shelf life is typically 36 months. Labels and documents are checked before dispatch.
> Pricing & MOQ
Pricing is quoted by specification, packaging and destination. Common commercial discussions use 25 kg bag/drum formats, pallet quantities and production-campaign planning; smaller samples may be reviewed for qualified formulation teams.
> Regulatory & Compounding Context
Toceranib phosphate is approved for veterinary use only. FDA-CVM approved in 2009 (Palladia, Zoetis) — the first targeted cancer therapy for animals. Not approved for human use (sunitinib is the structurally related human analog). EMA conditional authorization for EU markets. Under patent in some jurisdictions.
> Alias Index
- INN: Toceranib
- CAS Number: 356068-94-5 (phosphate)
- Formula: C₂₂H₂₂FN₅O (free base MW 395.44)
- Brand name: Palladia (Zoetis)
- ATCvet code: QL01EX90
- Pharmacological class: Multi-targeted RTK inhibitor (VEGFR, Kit, PDGFR)
- Related: Sunitinib (human analog, Sutent)
- Commercial request terms: toceranib phosphate API, Palladia generic, veterinary TKI, mast cell tumor drug, TCS Industries Limited
> FAQ
What tumor types respond to Toceranib Phosphate treatment?
Toceranib is approved for non-resectable Patnaik grade II/III canine mast cell tumors. Off-label use by veterinary oncologists includes carcinomas, sarcomas, and other Kit-dependent solid tumors in dogs. Response rates vary by tumor type and molecular profile. Buyers should reference current veterinary oncology literature for efficacy data.
What documents are available for Toceranib Phosphate orders?
COA and MSDS are standard for commercial discussions. COO, packing list, invoice and other import-support documents can be arranged according to order scope.
Do you supply Toceranib Phosphate to Australia and Canada?
Yes. We support B2B buyers in Australia, New Zealand, Canada and South Korea, subject to route and document review.
Do you supply New Zealand and South Korea?
Yes. We review Australia, New Zealand, Canada and South Korea for project supply, import documents, packaging and logistics planning before quotation.
Does Toceranib Phosphate require hazardous drug handling?
Yes. Toceranib is classified as a cytotoxic/antineoplastic agent. Manufacturing, formulation and dispensing must follow hazardous drug handling protocols (e.g., NIOSH guidelines). Closed-system transfer devices, PPE, and dedicated containment facilities are recommended during API processing and tablet manufacturing.
What is the relationship between Toceranib and Sunitinib?
Toceranib (SU-11654) and sunitinib (SU-11248, Sutent) are structurally related multi-target RTKI compounds developed by the same research program. Sunitinib is approved for human oncology (renal cell carcinoma, GIST). Toceranib was optimized for veterinary use and has a different kinase selectivity profile. They are different CAS numbers and different regulatory entities.
Can you arrange samples before commercial purchasing?
Samples or evaluation quantities may be reviewed for qualified buyers after target specification, application and destination-market requirements are clarified.
How is Toceranib Phosphate packaged for export?
Packaging is confirmed by quantity and material properties. Typical options include foil bags, HDPE containers, fibre drums, 25 kg bags or palletized export packaging.
Can buyer-defined specifications be reviewed?
Yes. Send the specification, methods, impurity limits and required documents. TCS can review feasibility before confirming quotation and lead time.
What payment terms are normally used?
Standard payment is 100% T/T before dispatch unless a different arrangement has been approved for an established commercial account.
What lead time should buyers expect?
Lead time depends on stock, batch size, document scope and destination. Available stock can move faster; made-to-order or pallet programs require longer planning.
What is the dosing schedule for Toceranib Phosphate in dogs?
Standard dosing for canine mast cell tumors is 3.25 mg/kg orally every other day. Tablet strengths (10 mg, 15 mg, 50 mg) are selected based on body weight. Dose adjustments are made based on adverse effect monitoring (CBC, urinalysis). API particle size and dissolution profile should match the target tablet design.
Last reviewed: June 2026
Evaluation and research orders (≤10 kg) are shipped with COA, MSDS, and certificate of origin. Bulk commercial orders (>10 kg) qualify for volume pricing with a full technical documentation package available on request.
> Request a Quote
If your team already has a target application, estimated quantity, destination market, or documentation requirements, send those details so the commercial response can be prepared more efficiently.